Novo Nordisk – the world’s largest insulin producer – and major diabetes drug manufacturers – could see BILLIONS in recurring revenue dry up as a small, California-based biotech company advances a technology that promises to change diabetes treatment. Over $100,000,000 has been invested in developing this super-drug that threatens to make products like Sanofi’s $6 …Read More